Home > Chemial News > Pharma News > Top 7 drugs most likely to become "blockbusters" in 2022

Top 7 drugs most likely to become "blockbusters" in 2022

Pharma time 2022-01-18

Recently, Clarivate Analytics analysts released a list of drugs predicted to be "blockbusters" in the future.


Criteria: Based on the "blockbuster" threshold of $1 billion in annual revenue, Clarivate Analytics predicts seven drugs that will reach $16 billion by the end of 2026. Among them, the top two drugs are likely to generate huge benefits.



Leading the list is Eli Lilly's diabetes drug tirzepatide, a dual GLP-1/GIP antagonist. Clarivate Analytics forecasts sales of the drug at $4.55 billion in 2026.



It is followed by the drug donanemab, also from Eli Lilly and Co., an Alzheimer's drug with projected 2026 sales of around $4.52 billion. The drug is currently undergoing several phase III trials.



Another anti-Alzheimer's disease drug from Biogen, Lecanemab, is an anti-Aβ fibrillar monoclonal antibody that is currently applying for breakthrough therapy and awaiting FDA review.



Alnylam's RNAi drug Vutrisiran, a drug for the rare disease ATTR (amyloid thyroxine), has few treatment options for a patient population. The drug not only taps into a relatively underserved market overall, but is more convenient than other ATTR-specific drugs on the market, analysts say.



Faricimab, the world's first dual VEGF/Ang-2 inhibitor for the treatment of DME (diabetic macular edema) and wet AMD (macular degeneration), is a collaboration between Genentech and Japan's Chugai. Faricimab is similar in efficacy to existing treatments, but is administered less frequently.



The anti-KRAS inhibitor adagrasib from Mirati. This is an anti-KRASG12C drug for NSCLC (non-small cell lung cancer) and CRC (colorectal cancer).

The drug received orphan drug and breakthrough therapy designation from the FDA last June. In November 2021, Mirati began its NDA filing.



Tezepelumab, a new asthma drug from AstraZeneca. Compared with existing treatments, Tezepelumab can better treat patients with low TH2 and non-TH2 asthma, and the market is broader.

Share to:
Disclaimer: ECHEMI reserves the right of final explanation and revision for all the information.

Trade Alert

Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)

Scan the QR Code to Share

Send Message